Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CFO Sells $185,536.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CFO Adam Laponis sold 4,160 shares of Twist Bioscience stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $185,536.00. Following the transaction, the chief financial officer now owns 89,237 shares of the company’s stock, valued at $3,979,970.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Adam Laponis also recently made the following trade(s):

• On Wednesday, October 9th, Adam Laponis sold 856 shares of Twist Bioscience stock. The stock was sold at an average price of $41.81, for a total value of $35,789.36.

Twist Bioscience Stock Down 0.3 %

TWST stock opened at $45.40 on Monday. The stock has a market capitalization of $2.66 billion, a P/E ratio of -11.88 and a beta of 1.78. Twist Bioscience Co. has a 52 week low of $15.85 and a 52 week high of $60.90. The firm has a 50-day simple moving average of $43.69 and a 200-day simple moving average of $45.74.

Analyst Ratings Changes

Several research firms have commented on TWST. Robert W. Baird upped their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Evercore ISI raised their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays decreased their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Finally, Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.22.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its stake in shares of Twist Bioscience by 34.8% in the first quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after acquiring an additional 44,349 shares during the last quarter. SageView Advisory Group LLC acquired a new stake in Twist Bioscience during the 1st quarter worth $1,144,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Twist Bioscience in the first quarter valued at about $300,000. Sei Investments Co. lifted its stake in shares of Twist Bioscience by 32.7% in the first quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after buying an additional 55,124 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC lifted its stake in shares of Twist Bioscience by 38.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after buying an additional 37,376 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.